TAS-2985
/ Otsuka
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 10, 2013
New challenges and inspired answers for anticancer drug discovery and development
(Jpn J Clin Oncol)
- PMID: 24014883; “Several promising programs are proceeding simultaneously in the clinical or preclinical development stage such as TAS-115, a dual inhibitor of c-Met and vascular endothelial growth factor receptor, TAS-2104, a selective Aurora A inhibitor, TAS-117, an allosteric Akt inhibitor, TAS-2985, an irreversible fibroblast growth factor receptor inhibitor and TAS-2913, a T790M mutant selective epidermal growth factor receptor inhibitor.”
Review • Oncology
1 to 1
Of
1
Go to page
1